These standardized methods were previously shown to detect NY-ESO-1-specific circulating CD4+ and CD8+ T cell responses only in NY-ESO-1-seropositive patients with NY-ESO-1-expressing tumor, but not in healthy donors with low frequency of precursors [4], [26]. This evidence concerns the gene CD4 and neoplasm.